Novel imidazolopyrimidines as dual PI3-kinase/mTor inhibitors

被引：0

作者：

Dehnhardt, Christoph ^{[1
]}

Venkatesan, Aranapakam ^{[1
]}

Chen, Zecheng ^{[1
]}

Delos Santos, Efren ^{[1
]}

Santos, Oswaldo ^{[1
]}

Bursavich, Matthew ^{[1
]}

Brooijmans, Natasja ^{[1
]}

Mallon, Robert ^{[1
]}

Hollander, Irwin ^{[1
]}

Feldberg, Larry ^{[1
]}

Lucas, Judy ^{[1
]}

Yu, Ker ^{[1
]}

Ayral-Kaloustian, Semiramis ^{[1
]}

Gibbons, Jay ^{[1
]}

Abraham, Robert ^{[1
]}

Mansour, Tarek ^{[1
]}

机构：

[1] Wyeth Res, Pearl River, NY USA

来源：

CANCER RESEARCH | 2009年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2017

引用

页数：1

共 50 条

[21] Beta-Testing of PI3-Kinase Inhibitors: Is Beta Better?
Shepherd, Peter R.
Denny, William A.
CANCER DISCOVERY, 2012, 2 (05) : 393 - 394
[22] Potent and highly selective benzimidazole inhibitors of PI3-Kinase delta
Sweeney, Zachary K.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
[23] Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta
Murray, Jeremy M.
Sweeney, Zachary K.
Chan, Bryan K.
Balazs, Mercedesz
Bradley, Erin
Castanedo, Georgette
Chabot, Christine
Chantry, David
Flagella, Michael
Goldstein, David M.
Kondru, Rama
Lesnick, John
Li, Jun
Lucas, Matthew C.
Nonomiya, Jim
Pang, Jodie
Price, Stephen
Salphati, Laurent
Safina, Brian
Savy, Pascal P. A.
Seward, Eileen M.
Ultsch, Mark
Sutherlin, Daniel P.
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (17) : 7686 - 7695
[24] Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Staben, Steven T.
Siu, Michael
Goldsmith, Richard
Olivero, Alan G.
Do, Steven
Burdick, Daniel J.
Heffron, Timothy P.
Dotson, Jenna
Sutherlin, Daniel P.
Zhu, Bing-Yan
Tsui, Vickie
Le, Hoa
Lee, Leslie
Lesnick, John
Lewis, Cristina
Murray, Jeremy M.
Nonomiya, Jim
Pang, Jodie
Prior, Wei Wei
Salphati, Laurent
Rouge, Lionel
Sampath, Deepak
Sideris, Steve
Wiesmann, Christian
Wu, Ping
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (13) : 4054 - 4058
[25] Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors
Ma, Cynthia X.
Crowder, Robert J.
Ellis, Matthew J.
STEROIDS, 2011, 76 (08) : 750 - 752
[26] Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR
Rewcastle, Gordon W.
Flanagan, Jack U.
Giddens, Anna C.
Gamage, Swarna A.
Tsang, Sophia K. Y.
Kendall, Jackie D.
Baguley, Bruce C.
Buchanan, Christina M.
Matthews, David J.
O'Farrell, Marie
Jamieson, Stephen M. F.
Denny, William A.
Shepherd, Peter R.
CANCER RESEARCH, 2014, 74 (19)
[27] Modulation of β-Catenin Signaling by the Inhibitors of MAP Kinase, Tyrosine Kinase, and PI3-Kinase Pathways
Zhang, Wenwen
Zhang, Hongyu
Wang, Ning
Zhao, Chen
Zhang, Hongmei
Deng, Fang
Wu, Ningning
He, Yunfeng
Chen, Xian
Zhang, Junhui
Wen, Sheng
Liao, Zhan
Zhang, Qian
Zhang, Zhonglin
Liu, Wei
Yan, Zhengjian
Luu, Hue H.
Haydon, Rex C.
Zhou, Lan
He, Tong-Chuan
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (13): : 1888 - 1898
[28] Collagen mRNA stability is regulated by mTOR via a PI3-kinase independent pathway
Shegogue, DA
Trojanowska, M
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 : 325A - 325A
[29] Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert
Y Wang
D Cai
N von Bubnoff
P Paschka
S Müller-Brüsselbach
O G Ottmann
J Duyster
A Hochhaus
A Neubauer
Leukemia, 2005, 19 : 1774 - 1782
[30] Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Burchert, A
Wang, Y
Cai, D
von Bubnoff, N
Paschka, P
Müller-Brüsselbach, S
Ottmann, OG
Duyster, J
Hochhaus, A
Neubauer, A
LEUKEMIA, 2005, 19 (10) : 1774 - 1782

← 1 2 3 4 5 →